1. Any concomitant illness that, based on the judgment of the Investigator might affect the interpretation or the results of the study (i.e., immunodeficiency, HIV etc.). 2. Patients with PO2< 60 at room air 3. Patients with PO2/FiO2<150 4. Patients with mechanical ventilation (ECMO), or NIV, or high flow nasal cannula) or using vasopressors or patients who will probably require ICU admission, mechanical ventilation, or the use of vasopressors within 24 hours from enrolment, according to the Investigator’s judgment 5. Pregnancy [positive urine pregnancy test (women of childbearing potential only)] or breastfeeding 6. Patient on long-term immunosuppression therapy, i.e., patient in active long-term inmmunosuppresion like rituximab 7. Participation in any other Interventional study in the last 30 days or within 5 half-lives of receiving an investigational agent.

1. Any concomitant illness that, based on the judgment of the Investigator might affect the interpretation or the results of the study (i.e., immunodeficiency, HIV etc.). 2. Patients with PO2< 60 at room air 3. Patients with PO2/FiO2<150 4. Patients with mechanical ventilation (ECMO), or NIV, or high flow nasal cannula) or using vasopressors or patients who will probably require ICU admission, mechanical ventilation, or the use of vasopressors within 24 hours from enrolment, according to the Investigator’s judgment 5. Pregnancy [positive urine pregnancy test (women of childbearing potential only)] or breastfeeding 6. Patient on long-term immunosuppression therapy, i.e., patient in active long-term inmmunosuppresion like rituximab 7. Participation in any other Interventional study in the last 30 days or within 5 half-lives of receiving an investigational agent.